Core Laboratories (NYSE:CLB - Free Report) had its price target reduced by Stifel Nicolaus from $19.00 to $15.00 in a research note published on Tuesday,Benzinga reports. Stifel Nicolaus currently has a hold rating on the oil and gas company's stock.
Separately, Citigroup upgraded shares of Core Laboratories from a "sell" rating to a "neutral" rating and raised their price objective for the company from $15.00 to $16.00 in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $15.75.
Read Our Latest Report on CLB
Core Laboratories Stock Performance
Shares of CLB traded up $0.26 during trading hours on Tuesday, hitting $12.58. The company's stock had a trading volume of 835,655 shares, compared to its average volume of 387,824. The business has a 50 day simple moving average of $14.53 and a two-hundred day simple moving average of $17.45. Core Laboratories has a 52-week low of $10.14 and a 52-week high of $25.13. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.32 and a quick ratio of 1.71. The company has a market cap of $587.28 million, a price-to-earnings ratio of 19.05, a PEG ratio of 0.99 and a beta of 1.99.
Core Laboratories (NYSE:CLB - Get Free Report) last issued its earnings results on Wednesday, January 29th. The oil and gas company reported $0.23 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.23. Core Laboratories had a net margin of 5.99% and a return on equity of 16.24%. On average, equities analysts expect that Core Laboratories will post 0.96 earnings per share for the current fiscal year.
Core Laboratories Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Monday, February 10th were issued a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a dividend yield of 0.32%. The ex-dividend date of this dividend was Monday, February 10th. Core Laboratories's payout ratio is 6.06%.
Institutional Investors Weigh In On Core Laboratories
A number of institutional investors and hedge funds have recently bought and sold shares of CLB. Assetmark Inc. purchased a new stake in shares of Core Laboratories during the 4th quarter valued at $26,000. Smartleaf Asset Management LLC raised its position in Core Laboratories by 173.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,037 shares of the oil and gas company's stock valued at $35,000 after purchasing an additional 1,293 shares in the last quarter. Nisa Investment Advisors LLC raised its position in Core Laboratories by 2,688.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,426 shares of the oil and gas company's stock valued at $42,000 after purchasing an additional 2,339 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Core Laboratories by 843.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,284 shares of the oil and gas company's stock worth $57,000 after purchasing an additional 2,936 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new position in shares of Core Laboratories during the 4th quarter valued at about $123,000. 97.81% of the stock is owned by hedge funds and other institutional investors.
Core Laboratories Company Profile
(
Get Free Report)
Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.
See Also
Before you consider Core Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Core Laboratories wasn't on the list.
While Core Laboratories currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
